{"filing":{"accession_number":"0001125345-26-000066","cik":"0001125345","ticker":"MGNX","company_name":"MACROGENICS INC","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"mgnx-20261023.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000066/mgnx-20261023.htm"},"events":[{"id":37589,"run_id":34640,"accession_number":"0001125345-26-000066","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"MacroGenics disclosed positive interim Phase 1 clinical trial results for MGC026, a B7-H3-directed antibody-drug conjugate, showing a 27% response rate in heavily pretreated SCCHN patients with a manageable safety profile. The company announced plans to initiate a front-line combination study with pembrolizumab in early 2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, exec changes, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity, dilutive issuance, litigation, debt/dividend issuance, or workforce reduction. It is clearly operational/strategic in nature—a significant product development update—making operational_other the most appropriate classification.","company_name":"MACROGENICS INC","ticker":"MGNX","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42351,"accession_number":"0001125345-26-000066","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MacroGenics disclosed positive interim Phase 1 clinical trial results for MGC026, a B7-H3-directed antibody-drug conjugate, showing a 27% response rate in heavily pretreated SCCHN patients with a manageable safety profile. The company announced plans to initiate a front-line combination study with pembrolizumab in early 2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, exec changes, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity, dilutive issuance, litigation, debt/dividend issuance, or workforce reduction. It is clearly operational/strategic in nature—a significant product development update—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:09:56.445597+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42351,"accession_number":"0001125345-26-000066","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MacroGenics disclosed positive interim Phase 1 clinical trial results for MGC026, a B7-H3-directed antibody-drug conjugate, showing a 27% response rate in heavily pretreated SCCHN patients with a manageable safety profile. The company announced plans to initiate a front-line combination study with pembrolizumab in early 2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, exec changes, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity, dilutive issuance, litigation, debt/dividend issuance, or workforce reduction. It is clearly operational/strategic in nature—a significant product development update—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:09:56.445597+00:00","company_name":"MACROGENICS INC","ticker":"MGNX","filing_date":"2026-10-23"}]}